文献速递骨质疏松与代谢性骨病

钙摄入对绝经后女性骨密度疗效及相关因素的定量分析

Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women.
PubMed 文献 · Osteoporos Int · 2017-03-23

该研究采用基于模型的荟萃分析方法,纳入17项试验共2537名受试者,定量分析钙摄入对绝经后女性骨密度(BMD)的疗效特征。研究发现年龄和钙摄入剂量是影响BMD变化效率和起效时间的关键因素,每日1200 mg钙被建议为有益剂量。

要点

  • 年龄和钙摄入剂量是影响BMD变化效率和起效时间的关键因素。
  • 60岁女性每日摄入800 mg钙,最大BMD提升率为2.38%,起效时间为9.44个月。
  • 每日1200 mg钙摄入2年可使BMD最大疗效达到81.3%,已进入平台期(>80% Emax)。

核心结论

  • 钙摄入可有效延缓绝经后女性BMD下降趋势,增加钙剂量有助于缩短起效时间。
  • 考虑药物起效速率和安全性,绝经后女性可给予合理剂量1200 mg/天以减少骨丢失。

研究设计与样本

  • 基于模型的荟萃分析(MBMA),在PubMed和EMBASE自2016年1月起进行全面文献检索。
  • 纳入安慰剂对照或无治疗对照的随机试验,聚焦钙摄入对绝经后女性骨质疏松的管理。
  • 共纳入17项试验,涉及2537名受试者。
  • 提取受试者临床和人口学特征及疗效数据,疗效定义为各观察时间点腰椎BMD(L2-L4)较基线的平均百分比变化。

主要发现

  • 经典药效学最大效应(Emax)模型可描述钙摄入后BMD变化的时间进程。
  • 60岁女性每日摄入800 mg钙,最大BMD提升率为2.38%,达到50%最大效应的时间(起效时间)为9.44个月。
  • 50至83岁女性最大效应值每年增加0.0817%。
  • 钙剂量间隔250至2000 mg/天时,起效时间表示为9.44 × (剂量/800)^-1.33个月。
  • 每日钙摄入700、1200和2000 mg持续两年,BMD最大疗效分别为68.0%、81.3%和89.6%,表明1200 mg/天剂量下最终疗效已达平台期(>80% Emax)。

关键数值与推荐

  • 每日1200 mg钙被建议为有益剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A model-based meta-analysis method was performed to quantitatively analyze the efficacy characteristics of calcium intake in BMD increase among postmenopausal women. We found that age and calcium intake dose were key factors affecting the efficiency and onset of BMD change, and daily 1200 mg calcium was suggested to be a beneficial dosage. INTRODUCTION: This paper aims to quantify the efficacy of calcium intake in preventing bone mineral density (BMD) decrease among postmenopausal women and to investigate the factors that may affect the efficacy. METHODS: Comprehensive literature search was conducted in PubMed and EMBASE from January 2016. Placebo-controlled or no-treatment controlled randomized trials focused on calcium intake for the management of osteoporosis in postmenopausal women were included. The clinical and demographic characteristics of participants and efficacy data, defined as the mean percentage change of spine BMD (L2-L4) at each observation time point compared with that of baseline, were extracted from the studies. Model-based meta-analysis (MBMA) was used to describe the time course of BMD change by calcium intake and identify the related factors. RESULTS: This study includes 17 trials involving 2537 subjects. The results showed that a classic pharmacodynamic maximal effect (E max) model could describe the time course of BMD change by calcium intake. Using this model, we found that age and calcium intake dose were key factors affecting the efficiency and onset of BMD change. A 60-year-old woman administered with 800 mg/day calcium can achieve a maximum BMD increasing rate of 2.38%, and the time to reach 50% of this maximum (known as onset time) was 9.44 months. An increase of 0.0817% per year was noted in the maximal effect value for women aged between 50 and 83 years. For calcium dose interval from 250 to 2000 mg/day, the onset time was expressed as 9.44 × (dose/800)-1.33 months. Two-year calcium intake of 700, 1200, and 2000 mg/day resulted in a maximum efficacy of BMD of 68.0, 81.3, and 89.6%, respectively. This indicates that the final efficacy had already reached the plateau (>80% E max) under the 1200-mg/day dose. CONCLUSION: Calcium intake can effectively postpone the tendency of BMD decrease in postmenopausal women. An increased calcium dose contributes to the shortening of the onset time. Considering the drug-acting rate and safety into account, menopausal women can be administered with a rational dose of 1200 mg/day to reduce bone loss.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Wu J, Xu L, Lv Y, et al. Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women. Osteoporos Int. 2017. PMID: 28337524. doi:10.1007/s00198-017-3993-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。